PPAR-&ggr; Agonists in Polycystic Kidney Disease with Frequent Development of Cardiovascular Disorders

E-ISSN： 1874-4702|5|2|292-300

ISSN： 1874-4672

Source： Current Molecular Pharmacology, Vol.5, Iss.2, 2012-06, pp. : 292-300

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

PPAR-&ggr; Agonists as Regulators of Microglial Activation and Brain Inflammation

Current Pharmaceutical Design, Vol. 12, Iss. 1, 2006-01 ,pp. : 93-109

Bentham Science Publishers

Access to resources Recommend Favorite

Peroxisome Proliferator-Activated Receptor (PPAR) Gamma Agonists as Therapeutic Agents for Cardiovascular Disorders: Focus on Atherosclerosis

Current Pharmaceutical Design, Vol. 23, Iss. 7, 2017-04 ,pp. : 1119-1124

Bentham Science Publishers

Access to resources Recommend Favorite

PPAR Agonists, Atherogenic Dyslipidemia and Cardiovascular Risk

Current Pharmaceutical Design, Vol. 23, Iss. 6, 2017-03 ,pp. : 894-902

Bentham Science Publishers

Access to resources Recommend Favorite

The PPAR genes, cardiovascular disease and the emergence of PPAR pharmacogenetics

By Cresci Sharon

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 15, 2005-12 ,pp. : 2577-2591

Informa Healthcare

Access to resources Recommend Favorite

Pharmacogenetics of the PPAR genes and cardiovascular disease

By Cresci Sharon

Pharmacogenomics, Vol. 8, Iss. 11, 2007-11 ,pp. : 1581-1595

Future Medicine

Access to resources Recommend Favorite